In specific cases of Community interest, the Director General of the Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail or the applicant shall refer the matter to the European Medicines Agency for application of the Community arbitration procedure before a decision is taken on the granting, variation, suspension or withdrawal of the marketing authorisation, in particular on the basis of pharmacovigilance data.